Suven Life Sciences is currently trading at Rs. 170.45, up by 3.00 points or 1.79% from its previous closing of Rs. 167.45 on the BSE.
The scrip opened at Rs. 168.80 and has touched a high and low of Rs. 172.40 and Rs. 168.00 respectively. So far 44955 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 228.50 on 30-May-2016 and a 52 week low of Rs. 151.10 on 09-Nov-2016.
Last one week high and low of the scrip stood at Rs. 169.90 and Rs. 164.00 respectively. The current market cap of the company is Rs. 2151.07 crore.
The promoters holding in the company stood at 60.00%, while Institutions and Non-Institutions held 7.32% and 32.68% respectively.
Suven Life Sciences (Suven) has secured one product patent from New Zealand (712369) corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and the Patent is valid through 2033. The granted claims of the patents are from the mechanism of action include the class of selective 5HT compounds and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Major Depressive disorder (MDD), Parkinson and Schizophrenia.
With these new patents, Suven has a total of 26 granted patents from New Zealand. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II.